LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

Executive Summary

• LIR Life Sciences announced the start of Project Phase 2 peptide design activities with Neuland Laboratories under the existing services agreement.
• Phase 2 will focus on structure‑activity relationship (SAR) analysis to create third‑generation cell‑penetrating peptides for the company’s transdermal delivery platform, aiming for improved synthetic efficiency and manufacturability.
• The work is intended to generate optimized peptide candidates that will guide future synthesis, formulation, and pre‑clinical testing programs.

Key Details

• Collaboration Scope: Continuation of the existing services agreement dated January 8 2026; Phase 2 follows successful completion of Phase 1 synthesis work.
• Project Objective: Design and optimization of next‑generation cell‑penetrating peptides to enhance transdermal transport activity while improving synthetic efficiency and formulation flexibility.
• Technical Approach: Systematic SAR analysis of synthetic variants derived from LIR’s lead protamine‑based sequences; identification of prioritized synthesis targets for downstream evaluation.
• Expected Outcomes: Generation of optimized peptide candidates that maintain strong transdermal delivery performance, improve manufacturability, and inform decisions on molecular design, quality attributes, and future development stages.
• CEO Quote: Edward Mills highlighted the significance of moving into Phase 2, emphasizing deeper SAR understanding to guide rational optimization and candidate selection for subsequent development phases.

Notable Quotes

“Advancing into Project Phase 2 design work with Neuland marks a meaningful step forward in the execution of our peptide development strategy,” said Edward Mills, CEO of LIR Life Sciences.

Materiality Assessment: Material – Positive (the announcement signals progress in a core R&D program that could materially affect future product pipelines and commercial potential).